Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Strasbourg, France
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Major patients who have received long-term treatment for NMO
Patients with a prospectively diagnosed NMO using the 2015 NMO classification criteria (IPND)
Patients who retrospectively meet the classification criteria of the 2015 NMO (IPND)
Patients who have not expressed their opposition, after information, to the reuse of their data for research purposes.
You may not be if
Patient who expressed his opposition to participating in the study
Lack of data on the assay of anti-AQP4 and anti-MOG antibodies
Less than a year of taking a second-line treatment before the relay
End of follow-up \<1 year following the transfer, this therefore includes patients whose transfer took place less than one year before the date of data extraction
Clareo Health | Safety of Therapeutic Step-down in Neuromyelitis Optica
